%0 Journal Article
%A Joseph, Nuradh
%A Cicchetti, Alessandro
%A McWilliam, Alan
%A Webb, Adam
%A Seibold, Petra
%A Fiorino, Claudio
%A Cozzarini, Cesare
%A Veldeman, Liv
%A Bultijnck, Renée
%A Fonteyne, Valérie
%A Talbot, Christopher J
%A Symonds, Paul R
%A Johnson, Kerstie
%A Rattay, Tim
%A Lambrecht, Maarten
%A Haustermans, Karin
%A De Meerleer, Gert
%A Elliott, Rebecca M
%A Sperk, Elena
%A Herskind, Carsten
%A Veldwijk, Marlon
%A Avuzzi, Barbara
%A Giandini, Tommaso
%A Valdagni, Riccardo
%A Azria, David
%A Jacquet, Marie-Pierre Farcy
%A Charissoux, Marie
%A Vega, Ana
%A Aguado-Barrera, Miguel E
%A Gómez-Caamaño, Antonio
%A Franco, Pierfrancesco
%A Garibaldi, Elisabetta
%A Girelli, Giuseppe
%A Iotti, Cinzia
%A Vavassori, Vittotorio
%A Chang-Claude, Jenny
%A West, Catharine M L
%A Rancati, Tiziana
%A Choudhury, Ananya
%T High weekly integral dose and larger fraction size increase risk of fatigue and worsening of functional outcomes following radiotherapy for localized prostate cancer.
%J Frontiers in oncology
%V 12
%@ 2234-943X
%C Lausanne
%I Frontiers Media
%M DKFZ-2022-02854
%P 937934
%D 2022
%X We hypothesized that increasing the pelvic integral dose (ID) and a higher dose per fraction correlate with worsening fatigue and functional outcomes in localized prostate cancer (PCa) patients treated with external beam radiotherapy (EBRT).The study design was a retrospective analysis of two prospective observational cohorts, REQUITE (development, n=543) and DUE-01 (validation, n=228). Data were available for comorbidities, medication, androgen deprivation therapy, previous surgeries, smoking, age, and body mass index. The ID was calculated as the product of the mean body dose and body volume. The weekly ID accounted for differences in fractionation. The worsening (end of radiotherapy versus baseline) of European Organisation for Research and Treatment of Cancer EORTC) Quality of Life Questionnaire (QLQ)-C30 scores in physical/role/social functioning and fatigue symptom scales were evaluated, and two outcome measures were defined as worsening in ≥2 (WS2) or ≥3 (WS3) scales, respectively. The weekly ID and clinical risk factors were tested in multivariable logistic regression analysis.In REQUITE, WS2 was seen in 28
%K fatigue (Other)
%K functional loss (Other)
%K integral dose (Other)
%K prostate cancer (Other)
%K radiotherapy - adverse effects (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:36387203
%2 pmc:PMC9645430
%R 10.3389/fonc.2022.937934
%U https://inrepo02.dkfz.de/record/182686